A phase I, open-label, dose-escalation study to assess the safety and tolerability of AT9283, a selective small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies

Trial Profile

A phase I, open-label, dose-escalation study to assess the safety and tolerability of AT9283, a selective small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jun 2009

At a glance

  • Drugs AT 9283 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Jun 2009 Results presented at ASCO 2009.
    • 16 May 2009 Status changed from not stated to completed.
    • 01 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top